BOULDER, CO / ACCESSWIRE / February 14, 2024 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 third quarter that ended December 31, 2023.
The Company posted quarterly product net revenue of $1.56 million and service net revenue of $20 thousand, or total net revenue of $1.58 million for a quarterly net loss of $207 thousand, or $(0.02) per diluted share. These results compare to product net revenue of $1.68 million and no service net revenue, or total net revenue of $1.68 million for a quarterly net loss of $216 thousand, or $(0.02) per diluted share, in the year-ago quarter. Gross margin on product net revenue was 46% in the fiscal 2024 third quarter and 53% in the fiscal 2023 third quarter.
The Company posted nine months product net revenue of $4.93 million and service net revenue of $134 thousand, or total net revenue of $5.06 million for a nine months net loss of $355 thousand, or $(0.03) per diluted share. These results compare to product net revenue of $5.08 million and service net revenue of $459 thousand, or total net revenue of $5.54 million for a nine months net loss of $231 thousand, or ($0.02) per diluted share, in the year-ago nine months. Gross margin on product net revenue was 48% in the fiscal 2024 nine months and 50% in the fiscal 2023 nine months.
"The fiscal 2024 third quarter presented significant challenges for Encision and for the medical device market in general," said Gregory Trudel, President and CEO of Encision Inc. "The demand for surgical procedures was diminished during the pandemic period and its rebound has been a slow process. The market has seen a number of positive indicators for an increase in demand and Encision continues to drive toward them. The service revenue that we were able to drive in the previous year was very helpful and we are starting to gain traction in recreating that revenue stream with a few new partners and opportunities to collaborate on our foundational technologies."
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2023 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Mala Ray, Encision Inc., 303-444-2600, This email address is being protected from spambots. You need JavaScript enabled to view it.
Encision Inc.
Unaudited Condensed Statements of Operations
(in thousands, except per share information)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | |||||||||||||
Product revenue | $ | 1,561 | $ | 1,684 | $ | 4,927 | $ | 5,084 | ||||||||
Service revenue | 20 | -- | 134 | 459 | ||||||||||||
Total revenue | 1,581 | 1,684 | 5,061 | 5,543 | ||||||||||||
Product cost of revenue | 843 | 786 | 2,539 | 2,528 | ||||||||||||
Service cost of revenue | 11 | -- | 69 | -- | ||||||||||||
Total cost of revenue | 854 | 786 | 2,608 | 2,528 | ||||||||||||
Gross profit | 727 | 898 | 2,453 | 3,015 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 414 | 502 | 1,237 | 1,494 | ||||||||||||
General and administrative | 352 | 360 | 1,107 | 1,103 | ||||||||||||
Research and development | 151 | 247 | 420 | 641 | ||||||||||||
Total operating expenses | 917 | 1,109 | 2,764 | 3,238 | ||||||||||||
Operating income (loss) | (190 | ) | (211 | ) | (311 | ) | (223 | ) | ||||||||
Interest expense and other income, net | (17 | ) | (5 | ) | (44 | ) | (8 | ) | ||||||||
(Loss) before provision for income taxes | (207 | ) | (216 | ) | (355 | ) | (231 | ) | ||||||||
Provision for income taxes | -- | -- | -- | -- | ||||||||||||
Net (loss) | $ | (207 | ) | $ | (216 | ) | $ | (355 | ) | $ | (231 | ) | ||||
Net (loss) per share-basic and diluted | $ | (0.02 | ) | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.02 | ) | ||||
Weighted average shares-basic and diluted | 11,770 | 11,763 | 11,770 | 11,761 | ||||||||||||
Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)
| December 31, 2023 | March 31, 2023 | |||||||
ASSETS | ||||||||
Cash | $ | 99 | $ | 189 | ||||
Accounts receivable | 923 | 921 | ||||||
Inventories, net | 1,554 | 1,899 | ||||||
Prepaid expenses | 129 | 116 | ||||||
Total current assets | 2,705 | 3,125 | ||||||
Equipment, net | 269 | 303 | ||||||
Right of use asset | 1,083 | 496 | ||||||
Patents, net | 166 | 163 | ||||||
Other assets | 64 | 47 | ||||||
Total assets | $ | 4,287 | $ | 4,134 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Accounts payable | $ | 302 | $ | 253 | ||||
Secured notes | 45 | 44 | ||||||
Line of credit | -- | 177 | ||||||
Accrued compensation | 233 | 218 | ||||||
Other accrued liabilities | 130 | 85 | ||||||
Accrued lease liability | 351 | 354 | ||||||
Total current liabilities | 1,061 | 1,131 | ||||||
Secured notes | 233 | 268 | ||||||
Accrued lease liability | 800 | 240 | ||||||
Total liabilities | 2,094 | 1,639 | ||||||
Common stock and additional paid-in capital | 24,401 | 24,348 | ||||||
Accumulated (deficit) | (22,208 | ) | (21,853 | ) | ||||
Total shareholders' equity | 2,193 | 2,495 | ||||||
Total liabilities and shareholders' equity | $ | 4,287 | $ | 4,134 | ||||
Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||||||||||||
| December 31, 2023 | December 31, 2022 | |||||||||||
Operating activities: | ||||||||||||
Net (loss) | $ | (355 | ) | $ | (231 | ) | ||||||
Adjustments to reconcile net (loss) to cash generated by (used in) operating activities: | ||||||||||||
Depreciation and amortization | 64 | 64 | ||||||||||
Share-based compensation expense | 53 | 39 | ||||||||||
Provision for inventory obsolescence, net | 63 | 53 | ||||||||||
Changes in operating assets and liabilities: | ||||||||||||
Right of use asset, net | (30 | ) | (31 | ) | ||||||||
Accounts receivable | (2 | ) | 118 | |||||||||
Inventories | 282 | (375 | ) | |||||||||
Prepaid expenses and other assets | (30 | ) | (28 | ) | ||||||||
Accounts payable | 49 | (274 | ) | |||||||||
Accrued compensation and other accrued liabilities | 60 | (73 | ) | |||||||||
Net cash generated by (used in) operating activities | 154 | (738 | ) | |||||||||
Investing activities: | ||||||||||||
Acquisition of property and equipment | (12 | ) | (173 | ) | ||||||||
Patent costs | (20 | ) | (10 | ) | ||||||||
Net cash (used in) investing activities | (32 | ) | (183 | ) | ||||||||
Financing activities: | ||||||||||||
Net proceeds from options exercised | -- | 21 | ||||||||||
Borrowings from secured notes | (212 | ) | 70 | |||||||||
Net cash (used in) provided by financing activities | (212 | ) | 91 | |||||||||
Net (decrease) in cash | (90 | ) | (830 | ) | ||||||||
Cash, beginning of period | 189 | 950 | ||||||||||
Cash, end of period | $ | 99 | $ | 120 | ||||||||
| Last Trade: | US$0.39 |
| Daily Change: | 0.04 11.43 |
| Daily Volume: | 6,500 |
| Market Cap: | US$4.630M |
November 15, 2024 August 21, 2024 August 15, 2024 July 15, 2024 November 14, 2023 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
